Mum left with bedsheet for loo door as council workers rip bathroom out and vanish
Laura Copestick said she had been forced to shower at the homes of friends and family daily for almost two months as her bathroom was rendered unusable.
She used a bed sheet as a toilet door for the most basic privacy and stale water had been left in the untiled bath at her Bartley Green council flat, she said.
READ MORE: Couple who starved their dog told RSPCA inspectors she was 'given to them by drug dealers'
Birmingham City Council said the work had now resumed.
Laura said she had spent around £1,000 of her own money on bathroom improvements before workers from the council told her they would be renovating it as it had to be "up to a standard."
Other homes owned by the authority also had the same work carried out in the area, she said.
But Laura said her project was never finished. She claimed the council 'cut the job' because she made complaints about the work.
READ MORE: In pictures: State of mum's bathroom after 'botched' council renovation
"They took every tile off the wall, annihilated the bathroom - it's still like that now," she said.
"There are holes everywhere. They ripped up my carpets, ruined them. The wall is falling down, they've tried to bodge it up.
"Hygiene boards are on backwards, I complained, they said it doesn't matter, but it does because it will leak. They didn't do it right so I kept making complaints.
"They said if I complained once time, they were cutting the job, leaving me without any bathing facilities for six weeks [now seven]."
"It's disgusting. I begged and begged, I've been on the phone 100 times a day to different people."
Laura said her mental health had been affected by the saga. During the project, her toilet door was removed, with the council telling her a replacement would come 'the same day'.
"But it never turned up," she explained.
"It's left me feeling really depressed, getting on the phone every day, being passed from pillar to post, and being told it's the first time they've knew about it, even though they've known a long time.
"It's just inhumane, it's basic human rights and no one seems to care."
Birmingham City Council said: "We are aware of the concerns raised by Ms Copestick regarding the bathroom renovation at her property and understand the impact this has had.
"Contractors initially began the work in late June but were asked to leave the property by our tenants following a breakdown in communication. We regret the delay this has caused.
"A new team of contractors began work on July 28 to complete the bathroom renovations. We expect the renovation to be completed by Friday or early next week.
"We are committed to ensuring all works are carried out as soon as possible and to a satisfactory standard."
Have you been affected by this? We would like to hear from you. You can contact us by emailing stephanie.balloo@reachplc.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
These medications could save thousands of lives – but doctors aren't prescribing them
In 2021, varenicline, the most effective single drug for quitting smoking, was withdrawn from the market in the UK because impurities were found at greater levels than is considered safe. Rapidly, varenicline (then sold under its brand names, Champix and Chantix) became unavailable. This was a disaster for public health. Research from University College London estimated that varenicline being unavailable resulted in about 1,890 more avoidable deaths each year because fewer people were successfully quitting smoking. But there was hope. Cytisine (also known as cytisinicline), a naturally occurring plant-based product that had been used for decades in Eastern Europe, and more recently to great effect elsewhere in the world, was licensed in the UK and made available from January 2024. Even so, there was an extended period when neither were available to people trying to quit smoking in the UK (and in other countries, too). But in the UK at least, things were looking up. Based on a limited but growing body of evidence, cytisine probably works as well as varenicline at helping people quit smoking, and it may be better tolerated with fewer side effects. It may also appeal to more smokers who may want to use a natural product rather than a drug designed in a lab. So, with varenicline withdrawn and a similarly effective treatment available, we should have seen lives saved as people who would have taken varenicline were encouraged to try cytisine instead. Why isn't anyone prescribing it? This didn't happen. Cytisine – despite now being licensed and available in the UK – is still shockingly underused. Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when it wasn't even officially available in the UK). Official NHS data from people accessing stop-smoking services in England confirm that only 0.7% were prescribed cytisine in 2024. So why is this? High-profile trials continue to show cytisine's effectiveness for quitting smoking (and even for quitting vaping). Maybe cytisine's relatively complex dosing schedule puts people off. Cytisine starts with six pills a day (one every two hours) and gradually tapers off over a few weeks: more confusing and less convenient than one-a-day varenicline. Another possibility is that the public's attention has shifted. With so much focus in recent years on vaping as a smoking cessation aid, prescription drugs for smoking cessation may have fallen off the radar. It could also be that GPs are reluctant to prescribe cytisine because of its cost and the assumption that local authorities should pay for it, not primary care. While it was once hoped that due to its low-cost availability in Eastern Europe, it would become the 'aspirin of smoking cessation drugs', the licensed product in the UK is now as or more expensive than other drugs. But the simplest explanation is probably the most accurate: not enough people know about cytisine. People who smoke, GPs, pharmacists and even stop-smoking services may not know it's an option. And if no one is talking about it, no one is prescribing it. And even if they do know about it, there may be a lack of confidence in using or prescribing it because it is a new drug. That's a problem. The UK government has made the shift from treating illness to preventing it a central part of its health strategy. Smoking remains the leading cause of preventable death in the country and the world. If we're serious about prevention, then effective smoking cessation support must be top of the agenda. Now, varenicline is available again (without its brand names and reformulated to remove the impurities). This is welcome news, but only 1.1% of past-year smokers reported using varenicline. That's only a quarter of the number from before its withdrawal. This raises an important question: should we return to prescribing varenicline by default, or is it time to consider cytisine as a first-line treatment? Researchers are continuing to learn more about cytisine, but as the evidence in favour of cytisine grows, maybe it needs a PR campaign for both prescribers and people who smoke. None of this is to say that cytisine is a miracle cure, or that it will work for everyone. But that's true of every way to help people quit smoking. Quitting smoking is hard, and people trying to quit need more options, not fewer, and those options need to be visible and accessible. Jonathan Livingstone-Banks is a Lecturer & Senior Researcher in Evidence-Based Healthcare at the University of Oxford. Dimitra Kale is a Senior Research Fellow in Health Psychology at UCL. Lion Shahab is a Professor in Health Psychology at UCL. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
4 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
Yahoo
9 hours ago
- Yahoo
Encompass Health reports results for second quarter 2025
Increases full-year guidance BIRMINGHAM, Ala., Aug. 4, 2025 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the second quarter ended June 30, 2025. Summary resultsGrowthQ2 2025Q2 2024DollarsPercent(In Millions, Except Per Share Data) Net operating revenue $ 1,457.7$ 1,301.2$ 156.512.0 % Income from continuing operations attributable toEncompass Health per diluted share 1.401.130.2723.9 % Adjusted earnings per share 1.401.110.2926.1 % Cash flows provided by operating activities 270.2217.452.824.3 % Adjusted EBITDA 318.6271.846.817.2 % Adjusted free cash flow 185.9142.543.430.5 % (Actual Amounts)Discharges 65,23760,8337.2 % Same-store discharge growth 4.7 % Net patient revenue per discharge $ 21,670$ 20,8034.2 % See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure. Revenue growth of 12.0% resulted from increased discharges and pricing. Total discharges grew 7.2%, inclusive of same-store growth of 4.7%. Net patient revenue per discharge grew 4.2%. Cash flows provided by operating activities increased 24.3% to $270.2 million, primarily due to an increase in net income. Adjusted EBITDA increased 17.2% from increased revenue and expense leverage. "During the quarter, we further increased our capacity to serve patients in need of inpatient rehabilitation care, opening a new 60-bed hospital in Fort Myers, Florida, and adding 26 beds to an existing hospital," said President and Chief Executive Officer Mark Tarr. "Our clinical expertise and commitment to delivering high-quality, cost-effective care continues to benefit our patients, referral sources and payors." 2025 Guidance The Company increased its full-year guidance as follows:Full-Year 2025 GuidancePrevious GuidanceUpdated Guidance(In Millions, Except Per Share Data) Net operating revenue $5,850 to $5,925$5,880 to $5,980 Adjusted EBITDA $1,185 to $1,220$1,220 to $1,250 Adjusted earnings per share from continuing operationsattributable to Encompass Health $4.85 to $5.10$5.12 to $5.34 For considerations regarding the Company's 2025 guidance, see the supplemental information posted on the Company's website at See also the "Other information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share. Earnings conference call and webcast The Company will host an investor conference call at 10:00 a.m. Eastern Time on Tuesday, August 5, 2025 to discuss its results for the second quarter of 2025. For reference during the call, the Company will post certain supplemental information at The conference call may be accessed by dialing 800 343-4849 and giving the conference ID EHCQ225. International callers should dial 203 518-9848 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at by clicking on an available link. About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 169 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, and Forbes' Most Trusted Companies in America.1 For more information, visit or follow us on our newsroom, X, Instagram and Facebook. 1 Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license. Other information The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "June 2025 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on August 4, 2025 (the "Q2 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at for reference during its August 5, 2025 earnings call. The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures. Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP. However, the following reasonably estimable GAAP measures for 2025 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted: Interest expense and amortization of debt discounts and fees - approximately $125 million Amortization of debt-related items - approximately $10 million The Q2 Earnings Form 8-K and, when filed, the June 2025 Form 10-Q can be found on the Company's website at and the SEC's website at Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited) Three Months Ended June 30,Six Months Ended June 30,2025202420252024(In Millions, Except Per Share Data) Net operating revenues $ 1,457.7$ 1,301.2$ 2,913.1$ 2,617.2 Operating expenses:Salaries and benefits 767.7700.51,530.01,412.1 Other operating expenses 213.8189.9431.3393.8 Occupancy costs 14.714.229.628.2 Supplies 63.157.6125.3116.1 General and administrative expenses 59.450.5111.7100.7 Depreciation and amortization 79.972.9159.1143.2 Total operating expenses 1,198.61,085.62,387.02,194.1 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Other income (6.7)(3.3)(9.2)(8.7) Equity in net income of nonconsolidated affiliates (1.4)(1.4)(2.3)(2.1) Income from continuing operations before income tax expense 236.8186.0475.4364.4 Provision for income tax expense 51.038.392.676.6 Income from continuing operations 185.8147.7382.8287.8 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income 184.9146.5381.4285.3 Less: Net income attributable to noncontrolling interests (42.8)(32.4)(87.8)(58.7) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Weighted average common shares outstanding:Basic 100.699.9100.699.9 Diluted 102.3102.0102.2102.1 Earnings per common share:Basic earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.42$ 1.14$ 2.92$ 2.28 Discontinued operations (0.01)(0.01)(0.01)(0.03) Net income $ 1.41$ 1.13$ 2.91$ 2.25 Diluted earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.40$ 1.13$ 2.88$ 2.24 Discontinued operations (0.01)(0.01)(0.01)(0.02) Net income $ 1.39$ 1.12$ 2.87$ 2.22 Amounts attributable to Encompass Health common shareholders:Income from continuing operations $ 143.0$ 115.3$ 295.0$ 229.1 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Encompass Health Corporation and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited) June 30, 2025December 31, 2024(In Millions) AssetsCurrent assets:Cash and cash equivalents $ 99.1$ 85.4 Restricted cash 38.337.7 Accounts receivable 612.5598.8 Other current assets 168.2165.0 Total current assets 918.1886.9 Property and equipment, net 3,820.33,643.1 Operating lease right-of-use assets 215.5203.7 Goodwill 1,303.01,284.0 Intangible assets, net 295.9297.8 Other long-term assets 232.9219.2 Total assets $ 6,785.7$ 6,534.7 Liabilities and Shareholders' EquityCurrent liabilities:Current portion of long-term debt $ 139.2$ 138.6 Current operating lease liabilities 25.526.3 Accounts payable 174.5171.0 Accrued expenses and other current liabilities 525.9505.1 Total current liabilities 865.1841.0 Long-term debt, net of current portion 2,320.32,359.2 Long-term operating lease liabilities 200.7189.7 Deferred income tax liabilities 110.6105.2 Other long-term liabilities 200.8190.4 Total liabilities 3,697.53,685.5 Commitments and contingenciesRedeemable noncontrolling interests 55.156.5 Shareholders' equity:Encompass Health shareholders' equity 2,280.12,067.0 Noncontrolling interests 753.0725.7 Total shareholders' equity 3,033.12,792.7 Total liabilities and shareholders' equity $ 6,785.7$ 6,534.7 Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30,20252024(In Millions) Cash flows from operating activities:Net income $ 381.4$ 285.3 Loss from discontinued operations, net of tax 1.42.5 Adjustments to reconcile net income to net cash provided by operating activities—Depreciation and amortization 159.1143.2 Stock-based compensation 23.822.9 Deferred tax expense 5.34.2 Other, net 1.114.2 Change in assets and liabilities, net of acquisitions—Accounts receivable (15.7)0.9 Other assets (16.5)(48.4) Accounts payable (2.5)1.8 Other liabilities 23.332.3 Net cash used in operating activities of discontinued operations (1.9)(2.7) Total adjustments 176.0168.4 Net cash provided by operating activities 558.8456.2 Cash flows from investing activities:Purchases of property, equipment, and intangible assets (320.0)(296.3) Proceeds from sale of restricted investments 132.017.0 Purchases of restricted investments (127.8)(8.2) Other, net (8.1)(0.6) Net cash used in investing activities (323.9)(288.1) Cash flows from financing activities:Principal payments on debt, including pre-payments (10.7)(2.4) Borrowings on revolving credit facility 60.050.0 Payments on revolving credit facility (80.0)(50.0) Principal payments under finance lease obligations (11.6)(10.7) Repurchases of common stock, including fees and expenses (56.8)(16.8) Dividends paid on common stock (35.1)(30.8) Distributions paid to noncontrolling interests of consolidated affiliates (73.3)(52.5) Taxes paid on behalf of employees for shares withheld (19.9)(12.1) Contributions from noncontrolling interests of consolidated affiliates —33.3 Other, net 6.81.8 Net cash used in financing activities (220.6)(90.2) Increase in cash, cash equivalents, and restricted cash 14.377.9 Cash, cash equivalents, and restricted cash at beginning of period 123.1104.2 Cash, cash equivalents, and restricted cash at end of period $ 137.4$ 182.1 Encompass Health Corporation and SubsidiariesSupplemental InformationEarnings Per Share Three MonthsEnded June 30,Six MonthsEnded June 30,2025202420252024(In Millions, Except Per Share Data) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Depreciation and amortization (79.9)(72.9)(159.1)(143.2) Interest expense and amortization of debt discounts and fees (30.4)(34.3)(62.2)(69.5) Stock-based compensation (14.3)(13.6)(23.8)(22.9) (Loss) gain on disposal or impairment of assets (0.3)3.0(0.5)(10.7)193.7154.0386.6298.5 Items not indicative of ongoing operating performance:Change in fair market value of equity securities 0.3(0.4)1.0(0.1) Asset impairment impact on noncontrolling interests ———7.3 Pre-tax income 194.0153.6387.6305.7 Income tax expense (51.0)(38.3)(92.6)(76.6) Income from continuing operations (1) $ 143.0$ 115.3$ 295.0$ 229.1 Basic shares 100.699.9100.699.9 Diluted shares 102.3102.0102.2102.1 Basic earnings per share (1) $ 1.42$ 1.14$ 2.92$ 2.28 Diluted earnings per share (1) $ 1.40$ 1.13$ 2.88$ 2.24 (1) Income from continuing operations attributable to Encompass Health Encompass Health Corporation and SubsidiariesSupplemental InformationAdjusted Earnings Per Share Q26 Months2025202420252024 Earnings per share, as reported $ 1.40$ 1.13$ 2.88$ 2.24 Adjustments, net of tax:Asset impairment impact ———0.02 Income tax adjustments —(0.02)(0.11)(0.03) Change in fair market value of equity securities ——(0.01)— Adjusted earnings per share* $ 1.40$ 1.11$ 2.77$ 2.23* Adjusted EPS may not sum due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Gain (loss) on sale of investments, excluding impairments 3.3(0.1)3.21.2 Equity in net income of nonconsolidated affiliates 1.41.42.32.1 Net income attributable to noncontrolling interests in continuing operations (42.8)(32.4)(87.8)(58.7) Amortization of debt-related items (2.4)(2.5)(4.8)(4.9) Distributions from nonconsolidated affiliates (0.9)(1.2)(1.4)(2.0) Current portion of income tax expense 54.540.687.372.4 Change in assets and liabilities 3.911.811.413.4 Cash used in operating activities of discontinued operations 1.22.01.92.7 Asset impairment impact on noncontrolling interests ———(7.3) Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Other 0.10.10.10.1 Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Three Months Ended June 30, 2025AdjustmentsAs ReportedIncome Tax AdjustmentsChange in Fair Market Valueof Equity SecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 318.6$ —$ —$ 318.6 Depreciation and amortization (79.9)——(79.9) Interest expense and amortization of debt discounts and fees (30.4)——(30.4) Stock-based compensation (14.3)——(14.3) Loss on disposal or impairment of assets (0.3)——(0.3) Change in fair market value of equity securities 0.3—(0.3)— Income from continuing operations before income tax expense 194.0—(0.3)193.7 Provision for income tax expense (51.0)0.40.1(50.5) Income from continuing operations attributable to Encompass Health $ 143.0$ 0.4$ (0.2)$ 143.2 Diluted earnings per share from continuing operations** $ 1.40$ —$ —$ 1.40 Diluted shares used in calculation 102.3* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per ShareFor the Three Months Ended June 30, 2024AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 271.8$ —$ —$ 271.8 Depreciation and amortization (72.9)——(72.9) Interest expense and amortization of debt discounts and fees (34.3)——(34.3) Stock-based compensation (13.6)——(13.6) Gain on disposal or impairment of assets 3.0——3.0 Change in fair market value of equity securities (0.4)—0.4— Income from continuing operations before income tax expense 153.6—0.4154.0 Provision for income tax expense (38.3)(2.4)(0.1)(40.8) Income from continuing operations attributable to Encompass Health $ 115.3$ (2.4)$ 0.3$ 113.2 Diluted earnings per share from continuing operations** $ 1.13$ (0.02)$ —$ 1.11 Diluted shares used in calculation 102.0* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2025AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 632.2$ —$ —$ 632.2 Depreciation and amortization (159.1)——(159.1) Interest expense and amortization of debt discounts and fees (62.2)——(62.2) Stock-based compensation (23.8)——(23.8) Loss on disposal or impairment of assets (0.5)——(0.5) Change in fair market value of equity securities 1.0—(1.0)— Income from continuing operations before income tax expense 387.6—(1.0)386.6 Provision for income tax expense (92.6)(11.6)0.3(103.9) Income from continuing operations attributable to Encompass Health $ 295.0$ (11.6)$ (0.7)$ 282.7 Diluted earnings per share from continuing operations** $ 2.88$ (0.11)$ (0.01)$ 2.77 Diluted shares used in calculation 102.2* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2024AdjustmentsAs Reported AssetImpairmentImpactIncome Tax AdjustmentsChange in FairMarket Valueof EquitySecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 544.8 $ —$ —$ —$ 544.8 Depreciation and amortization (143.2) ———(143.2) Interest expense and amortization of debt discounts and fees (69.5) ———(69.5) Stock-based compensation (22.9) ———(22.9) Loss on disposal or impairment of assets (10.7) 10.4——(0.3) Change in fair market value of equity securities (0.1) ——0.1— Asset impairment impact on noncontrolling interests 7.3 (7.3)——— Income from continuing operations before income tax expense 305.7 3.1—0.1308.9 Provision for income tax expense (76.6) (1.3)(3.0)—(80.9) Income from continuing operations attributable to Encompass Health $ 229.1 $ 1.8$ (3.0)$ 0.1$ 228.0 Diluted earnings per share from continuing operations** $ 2.24 $ 0.02$ (0.03)$ —$ 2.23 Diluted shares used in calculation 102.1 * See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Income to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net income $ 184.9$ 146.5$ 381.4$ 285.3 Loss from discontinued operations, net of tax, attributable to Encompass Health 0.91.21.42.5 Net income attributable to noncontrolling interests included in continuing operations (42.8)(32.4)(87.8)(58.7) Provision for income tax expense 51.038.392.676.6 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Depreciation and amortization 79.972.9159.1143.2 Loss (gain) on disposal or impairment of assets 0.3(3.0)0.510.7 Stock-based compensation 14.313.623.822.9 Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Asset impairment impact on noncontrolling interests ———(7.3) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months EndedJune 30,Six Months Ended June 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Impact of discontinued operations 1.22.01.92.7 Net cash provided by operating activities of continuing operations 271.4219.4560.7458.9 Capital expenditures for maintenance (45.1)(48.9)(79.1)(87.6) Distributions paid to noncontrolling interests of consolidated affiliates (40.4)(27.8)(73.3)(52.5) Items not indicative of ongoing operating performance:Transaction costs and related liabilities —(0.2)—(8.7) Adjusted free cash flow $ 185.9$ 142.5$ 408.3$ 310.1 For the three months ended June 30, 2025, net cash used in investing activities was $165.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2025 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the three months ended June 30, 2024, net cash used in investing activities was $158.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2024 was $49.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. For the six months ended June 30, 2025, net cash used in investing activities was $323.9 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2025 was $220.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the six months ended June 30, 2024, net cash used in investing activities was $288.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2024 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. Encompass Health Corporation and SubsidiariesForward-Looking Statements Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health's services, including based on any downturns in the economy, consumer confidence, or the capital markets; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; Encompass Health's ability to realize construction time and cost savings from prefabrication of hospitals; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2024 and Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, when filed. Media ContactPolly Manuel, 205 Investor Relations ContactMark Miller, 205 View original content to download multimedia: SOURCE Encompass Health Corp.